News
12.March 10Ambicare on Sky NewsRead more on Ambicare’s new product, the Ambulight, at
Sky.com and watch the Sky News reports online.
10.March 10Julian Hickman writes for Investment AdviserJulian Hickman, Longbow Partner, has been featured in Investment Adviser this week writing on EIS investment. Read the article entitled ’Focus: Enterprise worth investigating’ by clicking the link below.
Investment Adviser10.March 10Read reviews about the Longbow EIS FundsReviews on Longbow’s EIS Funds are now available in Martin Churchill’s
Tax Efficient Review and
Allenbridge’s Tax Shelter Report.
17.February 10Takeda invests in DomainexClick here to read the latest news from Domainex.
17.February 10Longbow Newsletter February 2010Please
click here to read Longbow’s latest newsletter.
10.February 10Longbow Approved EIS Fund LaunchThe announcement of the launch of our latest Fund, the Longbow
Approved EIS Fund 2010 has generated significant coverage in the IFA press.
Click on the links below to read more.
Private Equity WireUnquote
Fund Strategy
Investment Adviser05.February 10Longbow Launches Approved EIS Fund 2010Please
click here to read the press release.
28.January 10Read our blogLongbow has recently launched a blog.
Click here to read articles, discussions and the latest news from Longbow Capital.19.October 09Longbow Newsletter Autumn 2009Please
click here to read our latest newsletter.
28.September 09Breastlight in Boots
The Breastlight is now on sale in Boots stores and online at www.boots.com.
This follows a successful launch in Canada through Rexall, the leading Canadian pharmacy chain.
The device has received an impressive amount of press coverage in recent weeks and has been seen in Good Housekeeping, Health & Fitness, More Magazine, Women’s Own and most recently in Cosmopolitan.
28.September 09Longbow invests in Calon Cardio Technology
Longbow is pleased to announce that we have completed an investment into Calon Cardio Technology, a developer of novel heart pumps.
Calon Cardio’s designs are unique in that they can be implanted using minimally invasive procedures rather than open heart surgery.
25.September 09Ambicare recieves CE markingLongbow portfolio company Ambicare has achieved CE marking for its lead product the ’Ambulight, which treats non melanoma skin cancer. It can now actively market its product in the European Union.
20.September 09Lumicure changes name to Ambicare
Longbow portfolio company Lumicure Ltd, which is developing light-based treatments for skin cancer and acne, has changed its name to
Ambicare.
Ambicare has recently completed development of its lead product (Ambulight) for the treatment of non melanoma skin cancer.
14.September 09Polytherics collaborates with MinapharmLongbow portfolio company PolyTherics Limited today announced the initiation of a research collaboration agreement with Minapharm Pharmaceuticals, the leading Egyptian pharmaceutical company. PolyTherics will apply its proprietary drug modification technologies to a target protein of commercial interest to Minapharm.
01.September 09Biotronics opens Innovation CentreBiotronics3D has opened an Innovation Centre in Cambridge, UK to boost its research and development capabilities. The strategic location next to a world leading academic institution and in the heart of several unique medical technology clusters will allow the company to accelerate the development of novel components for its future products.
03.July 09Domainex collaborates with St George’s HospitalDomainex Ltd, St George’s University of London and the University of Manchester today announced that they are collaborating on a new drug discovery programme to provide a better treatment for asthma.
Click here to read the full press release.
03.July 09Domainex and Ark Therapeutics extend drug discovery agreementDomainex have announced an extension of its research agreement with Ark Therapeutics Group Ltd.
Click here to read the full press release.
11.May 09Venture investment in SIPPs - Do the MathsCareful research and informed decision-making can help greatly in using SIPPs to construct clients’ investment portfolios, control risk and boost growth.
Julian Hickman, Longbow Partner, discusses the benefits of venture investment within SIPPs in the Investment Adviser.
Read the full story online in the
Investment Adviser07.April 09Longbow’s Keith Powell in the Financial TimesLongbow Partner, and Polytherics CEO, Keith Powell was featured in the Financial Times today, describing investment in Biotech as ’in terms of employment and developing the economy, biotech is extremely good value for money".
Read the full story in the
FT Online.
06.April 09Longbow Launches SIPP Venture FundAXA Winterthur Wealth Management now offers the first SIPP venture fund from
Longbow Capital, via The One from Winterthur.
Read the full story in:
Citywire IFA OnlineAXA Winterthur’s Website FT OnlineOr
click here to read the full press release.
30.March 09Longbow Partner Ron Petersen
Boots Centre for Innovation in Swansea has appointed Ron Petersen as its new CEO.
Ron Petersen has been involved in the Boots Centre for Innovation since its inception in 2007, and has played an instrumental role in shaping the organisation’s business model. He has provided valuable advice on how to progress ideas received by the Centre, and is well-positioned to lead the Centre forward in 2009.
Visit
www.bootsinnovation.com/news.html to read more.
23.March 09Longbow reaches for the SkyRecent Investment - Sky Medical Longbow has just completed an investment into medical device company, Sky Medical. Sky Medical is commercializing a range of products based on technology developed at St Barts Hospital London; initially for the prevention of deep vein thrombosis but also for cardiovascular disease and improved circulation.
The investment will enable Sky Medical to launch its products into hospitals and pharmacies later this year. Sky Medical is the fourth investment in technology that can take advantage of Longbow’s relationship with the Boots Centre for Innovation.
Investors can access innovative life sciences companies like Sky Medical through the Longbow EIS Funds. For further information please call Julian Hickman or Nicola Robson on 020 7332 0320.
20.March 09Domainex and Breakthrough Breast CancerInnovative drug discovery company, Domainex, collaborates with Breakthrough Breast Cancer and Institute of Cancer Research on novel drug targets.
Please
click here to read the full press release.
11.March 09Longbow Newsletter Spring 2009Includes recent news from our Portfolio companies, details of recent investment, Sky Medical, and Longbow Partner Edward Rudd’s take on Healthcare and Venture Capital in a Recession.
Please
click here to download the newsletter.